BioMarin Pharmaceutical Inc.

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

10 сен 2019 09:45:06 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

09 сен 2019 09:50:21 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

15 авг 2019 09:45:01 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

14 авг 2019 09:45:02 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

13 авг 2019 09:45:00 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

12 авг 2019 11:44:24 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

06 авг 2019 10:30:54 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

05 авг 2019 10:11:20 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

02 авг 2019 09:45:02 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

31 июл 2019 15:08:40 Источник NetDania Notify

NetDania - New 12 months Low: BioMarin Pharmaceutical Inc.

30 июл 2019 09:47:08 Источник NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

17 окт 2018 10:48:59 Источник NetDania Notify

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

12 дек 2016 08:29:22 Источник Nasdaq GlobeNewswire

BioMarin to Attend Three Upcoming Investor Conferences

03 ноя 2016 08:30:46 Источник Nasdaq GlobeNewswire

BioMarin Announces Third Quarter 2016 Financial Results

27 окт 2016 16:03:46 Источник Nasdaq GlobeNewswire

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

19 окт 2016 17:01:21 Источник Nasdaq GlobeNewswire

UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A

13 окт 2016 16:01:29 Источник Nasdaq GlobeNewswire

BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET

11 окт 2016 08:31:09 Источник Nasdaq GlobeNewswire

BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics

21 сен 2016 08:54:15 Источник Nasdaq GlobeNewswire

BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

15 сен 2016 08:38:09 Источник Nasdaq GlobeNewswire